Skip to content
Screener

Ligand Pharmaceuticals LGND Financing Cash Flow

Financing Cash Flow at other companies

Royalty Pharma logo
Royalty PharmaRPRX
-$273.15M+46.2%
Roivant Sciences logo
Roivant SciencesROIV
-$181.51M+3.3%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$323.74M
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$412.29M-33,163%
Innoviva, Inc. logo
Innoviva, Inc.INVA
-$29.41M-2,458%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
-$10.92M-2,356%

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886163-26-000044
Net proceeds from stock option exercises and ESPP16,25512,461
Taxes paid related to net share settlement of equity awards(22,075)(9,036)
Proceeds from Pelthos investors6,910
Net cash provided by financing activities532,30110,248
Effect of exchange rate changes on cash and cash equivalents(5)3,350
Net increase (decrease) in cash, cash equivalents and restricted cash, including cash and cash equivalents classified within assets held for sale831,775(1,821)
Less: net increase in cash and cash equivalents classified within assets held for sale(2,817)
Net increase (decrease) in cash, cash equivalents and restricted cash831,775(4,638)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's financing cash flow?
Ligand Pharmaceuticals (LGND) reported financing cash flow of $546.43M in Q2 2026.
How has Ligand Pharmaceuticals's financing cash flow changed year-over-year?
Ligand Pharmaceuticals's financing cash flow increased by 3544.1% year-over-year, from $15M to $546.43M.
What is the long-term trend for Ligand Pharmaceuticals's financing cash flow?
Over 3 years (2021 to 2025), Ligand Pharmaceuticals's financing cash flow has grown at a 44.5% compound annual growth rate (CAGR), from -$141.93M to $428.22M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Ligand Pharmaceuticals's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude